Evidence map›Paper›PMID 41029921›Full record

ReviewCurrent drug metabolism2025

TOX4 Inhibition in Chronic Hyperglycemia: Effects on Glycation Stress, Hepatic Protection, Epigenetic Mechanisms, Signaling Pathways, and Beta Cell Dynamics.

Bonthu Varunteja, Nayan Gupta, Anjali Kumari, Tuhin Mukherjee, Satyajit Mohanty, Nikita Nayak, Mahendra Pratap Chopra, Ashok Pattnaik

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bonthu VaruntejaDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.
Nayan GuptaDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.
Anjali KumariDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.
Tuhin MukherjeeDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.ORCID 0000-0002-8114-9952
Satyajit MohantyDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.ORCID 0000-0001-6665-3432
Nikita NayakDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.
Mahendra Pratap ChopraDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.
Ashok PattnaikDivision of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, Jharkhand, India.ORCID 0000-0003-2931-9042

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TOX high mobility group box family member 4 (TOX4) has emerged as a critical regulator of Hepatic Glucose Production (HGP), particularly under insulin-resistant conditions seen in Type 2 Diabetes Mellitus (T2DM). Hyperglycemia-induced formation of Advanced Glycation End products (AGEs) exacerbates metabolic dysfunction. While the Akt- FoxO1 axis has been the conventional focus of insulin signaling, recent findings highlight the upregulation of TOX4 in T2DM, obesity, and preclinical models (e.g., db/db mice). The cAMP signaling pathway has been shown to modulate TOX4 expression. This review synthesizes findings from recent

Indexed as

High Mobility Group ProteinsHyperglycemiaAnimalsDiabetes Mellitus, Type 2Epigenesis, GeneticGlucoseGlycation End Products, AdvancedHumansInsulin-Secreting CellsLiverSignal TransductionGlucoseGlycation End Products, AdvancedHigh Mobility Group Proteinsdiabetes mellitusdiabetic neuropathyinsulin resistance.liver damagesmall molecule inhibitorTOX4Type 2 diabetes mellitus

Identifiers

PMID41029921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.